KRAS mutational testing in the selection of patients for EGFR-targeted therapies
To access this article, please choose from the options below
PII: S0740-2570(08)00067-1
doi:10.1053/j.semdp.2008.08.003
© 2008 Elsevier Inc. All rights reserved.
PII: S0740-2570(08)00067-1
doi:10.1053/j.semdp.2008.08.003
© 2008 Elsevier Inc. All rights reserved.